Subscribe Now!

 

Wednesday, September 22, 2021

Partnership of CEM Corporation and AmbioPharm, Inc.

Latest articles

CreatorIQ Expands Its Leadership Position With Acquisition of #1 Influencer Marketing Analytics Platform

Influencer marketing platform, CreatorIQ -- the most trusted partner advancing the creator economy for brands like AB InBev, Disney, Sephora, and Unilever -- today...

LET THE OLYMPIC GAMES COME HOME!

By Aris Michopoulos, Ph.D. THE PAST For over a thousand years (776 BC – 394 AD) the Olympic Games were the premier event of Greece that...

GREECE: The first flight with drone for the transport of drugs,

Some years ago it seemed like a science fiction script. Today it is a reality, which can provide many solutions in emergency situations, helping...

ΕΛΛΑΔΑ: Μεταφορά φαρμακευτικού υλικού με drone!

Πριν κάποια χρόνια φάνταζε ως σενάριο επιστημονικής φαντασίας. Σήμερα είναι μια πραγματικότητα, η οποία μπορεί να δώσει πολλές λύσεις σε συνθήκες έκτακτης ανάγκης, βοηθώντας...

Διεθνές συνέδριο Αρχαίου Δράματος – Διαθέσιμο και Online

Το Εθνικό Θέατρο με το Ελληνικό Ίδρυμα Πολιτισμού, στο πλαίσιο του προσφάτως υπογεγραμμένου μνημονίου συνεργασίας, συμπράττουν για τη δυναμική προώθηση της θεατρικής παιδείας και...

International Conference on Ancient Drama – Available online

The National Theater and the Hellenic Foundation for Culture, in the context of the recently signed memorandum of cooperation, collaborate for the dynamic promotion...

The Greek market wants targeted offers and personalized messages

The majority of consumers react more positively than ever to targeted offers and personalized messages, according to Qivos. "These are offers and messages that support...

CEM Corporation and AmbioPharm, Inc. are excited to announce the formation of a partnership for production of GMP peptides for the global market. The partnership will involve an exclusive1 use of CEM’s large-scale microwave peptide synthesis technology for the production of GMP peptides up to multi-kilogram quantities using proprietary scalable reactors. The key benefits of this new relationship are extremely rapid production times, the ability to efficiently produce more difficult peptide sequences, and the ability to incorporate green chemistry protocols. This partnership will enable rapid and efficient production of peptide new chemical entities (NCE’s) using the latest technologies available. With this agreement, AmbioPharm has commenced peptide synthesis operations in its North Augusta facility to better serve customers with expedited microwave synthesis capabilities.

CEM’s technology for peptide production utilizes automated large-scale microwave solid-phase peptide synthesis (SPPS) systems that have been established for improving peptide purity and minimizing excess reagents needed. Additionally, CEM has developed proprietary coupling methodologies optimized for elevated temperature reactions2, a unique way to combine the coupling and deprotection reactions into a single step3, and established the use of greener solvents that are more accessible using elevated temperatures4. These unique technology benefits will be licensed to AmbioPharm for GMP production.

AmbioPharm is a recognized leader in cGMP peptide production. The company employs more than 675 employees and recently completed a major expansion at its headquarters in South Carolina, US, adding nearly 56,000 sq. ft of additional peptide manufacturing capacity. The production facility has the purification capability of up to 30 kg/batch and a lyophilization capacity of up to 1,000L. The CEM Liberty Pro synthesizer offers differing reactor sizes (3, 8 and 15 liter) allowing synthesis of batches from 5 g to 500 g of final peptide.

“Peptide based drugs have enormous potential for the future and we are excited to contribute to improving their production process. AmbioPharm is an ideal partner, and we believe this relationship will provide enhanced capabilities for the production of peptide therapeutics.” – Michael J. Collins, Ph.D., President & CEO of CEM Corporation.

“With the addition of CEM’s microwave technology into our GMP peptide manufacturing options, we can offer even better service in terms of expedited delivery for our partners’ products as well as unique capabilities for making longer and more complex peptides accessible with microwave methods.” – Chris Bai, Ph.D., CEO of AmbioPharm Inc.

Thanks for reading Hellenic News of America

Both companies will be exhibiting at the upcoming TIDES USA conference in September 2021.

About CEM

CEM Corporation, a private company based in Matthews, North Carolina, is a leading provider of laboratory instrumentation. The company has subsidiaries in the United Kingdom, Germany, Italy, France, Japan, and Singapore, as well as a global network of distributors. CEM designs and manufactures systems for life sciences, analytical laboratories and processing plants worldwide. The company’s products are used in many industries including pharmaceutical, biotech, chemical and food processing, as well as academic research. Further information is available at: https://www.cem.com.

About AmbioPharm, Inc.

AmbioPharm, a part of the Ambio Pharmaceuticals Group, is a leading and innovation-driven company specializing in the development and manufacture of peptides and peptide-related products. With a comprehensive range of services, AmbioPharm produces custom products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. Headquartered in the United States of America and with locations in Europe, the USA, and Asia, AmbioPharm operates internationally with over 14 years of experience and expertise. Further information is available at: https://www.ambiopharm.com.

SOURCE: AMNA

The copyrights for these articles are owned by the Hellenic News of America. They may not be redistributed without the permission of the owner. The opinions expressed by our authors do not necessarily reflect the opinions of the Hellenic News of America and its representatives.

Get Access Now!